Astellas Pharma Inc. and UMN Pharma Inc. today announced that the summary results for Phase III clinical trials showed non-inferiority of the recombinant seasonal influenza HA vaccine UMN-0502 (ASP7374) in comparison with the egg-derived vaccine in terms of immunogenicity. No major safety problem was also observed in UMN-0502 (ASP7374) in this study.